Point-mutation products of Ras proto-oncogene are found to associated with a broad spectrum of human carcinomas. Mutation locations are notably at codons 12, 13, and 61. Codon 12 mutations form more than 90% of all Ras mutations in human cancers. Degraded Ras peptides have been shown to stimulate immunogenic response. Various forms of mutated Ras peptides-adjuvant are used as vaccine along with cytokines that could potentially enhance the body's immunological response in many neoplastic conditions. (NCI04)